353 related articles for article (PubMed ID: 33077920)
1. Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
Lin DI; Killian JK; Venstrom JM; Ramkissoon SH; Ross JS; Elvin JA
Mod Pathol; 2021 May; 34(5):983-993. PubMed ID: 33077920
[TBL] [Abstract][Full Text] [Related]
2. Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.
D'Angelo E; Espinosa I; Felicioni L; Buttitta F; Prat J
Hum Pathol; 2023 Nov; 141():15-21. PubMed ID: 37673346
[TBL] [Abstract][Full Text] [Related]
3. Ovarian transitional cell carcinoma represents a poorly differentiated form of high-grade serous or endometrioid adenocarcinoma.
Takeuchi T; Ohishi Y; Imamura H; Aman M; Shida K; Kobayashi H; Kato K; Oda Y
Am J Surg Pathol; 2013 Jul; 37(7):1091-9. PubMed ID: 23681072
[TBL] [Abstract][Full Text] [Related]
4. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications.
Logani S; Oliva E; Amin MB; Folpe AL; Cohen C; Young RH
Am J Surg Pathol; 2003 Nov; 27(11):1434-41. PubMed ID: 14576476
[TBL] [Abstract][Full Text] [Related]
5. MDM2 amplification in malignant Brenner tumors may play a role in progression to malignancy and aid in separation from urothelial and other ovarian carcinomas.
Shetty S; Habeeb O; Rivera C; Astbury C; Przybycin C; Joehlin-Price AS
Hum Pathol; 2021 Nov; 117():42-50. PubMed ID: 34391746
[TBL] [Abstract][Full Text] [Related]
6. Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology.
Pfarr N; Darb-Esfahani S; Leichsenring J; Taube E; Boxberg M; Braicu I; Jesinghaus M; Penzel R; Endris V; Noske A; Weichert W; Schirmacher P; Denkert C; Stenzinger A
Genes Chromosomes Cancer; 2017 Oct; 56(10):758-766. PubMed ID: 28639280
[TBL] [Abstract][Full Text] [Related]
7. [Dualistic classification of epithelial ovarian cancer: Is it clinically relevant?].
Devouassoux-Shisheboran M; Genestie C; Ray-Coquard I
Bull Cancer; 2016 Mar; 103(3):252-8. PubMed ID: 26853278
[TBL] [Abstract][Full Text] [Related]
8. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas.
Cuatrecasas M; Catasus L; Palacios J; Prat J
Am J Surg Pathol; 2009 Apr; 33(4):556-67. PubMed ID: 19033864
[TBL] [Abstract][Full Text] [Related]
9. Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor.
Ali RH; Seidman JD; Luk M; Kalloger S; Gilks CB
Int J Gynecol Pathol; 2012 Nov; 31(6):499-506. PubMed ID: 23018212
[TBL] [Abstract][Full Text] [Related]
10. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
[TBL] [Abstract][Full Text] [Related]
11. Benign and Malignant Brenner Tumors Show an Absence of TERT Promoter Mutations That Are Commonly Present in Urothelial Carcinoma.
Khani F; Diolombi ML; Khattar P; Huang W; Fallon JT; Epstein JI; Zhong M
Am J Surg Pathol; 2016 Sep; 40(9):1291-5. PubMed ID: 27299795
[TBL] [Abstract][Full Text] [Related]
12. Brenner tumors but not transitional cell carcinomas of the ovary show urothelial differentiation: immunohistochemical staining of urothelial markers, including cytokeratins and uroplakins.
Riedel I; Czernobilsky B; Lifschitz-Mercer B; Roth LM; Wu XR; Sun TT; Moll R
Virchows Arch; 2001 Feb; 438(2):181-91. PubMed ID: 11253121
[TBL] [Abstract][Full Text] [Related]
13. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
Ramalingam P
Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
[TBL] [Abstract][Full Text] [Related]
14. Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Jin JS; Hsieh DS; Loh SH; Chen A; Yao CW; Yen CY
Mod Pathol; 2006 Mar; 19(3):447-52. PubMed ID: 16439987
[TBL] [Abstract][Full Text] [Related]
15. Endometroid adenocarcinoma of the uterus, borderline tumor of the ovary and Brenner tumor of the contralateral ovary in a 63-year-old woman.
Krepinska E; Kriz JT; Laco J
Eur J Gynaecol Oncol; 2010; 31(5):584-5. PubMed ID: 21061809
[TBL] [Abstract][Full Text] [Related]
16. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.
Kurman RJ; Shih IeM
Am J Surg Pathol; 2010 Mar; 34(3):433-43. PubMed ID: 20154587
[TBL] [Abstract][Full Text] [Related]
17. The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis.
Kuhn E; Ayhan A; Shih IeM; Seidman JD; Kurman RJ
Mod Pathol; 2014 Feb; 27(2):231-7. PubMed ID: 23887305
[TBL] [Abstract][Full Text] [Related]
18. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.
Kurman RJ; Shih IeM
Hum Pathol; 2011 Jul; 42(7):918-31. PubMed ID: 21683865
[TBL] [Abstract][Full Text] [Related]
20. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
